Tumour heterogeneity: principles and practical consequences (Q38842168)

6 September 2017

1 reference

title

Tumour heterogeneity: principles and practical consequences (English)

1 reference

6 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Serena Bonin

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gerald Hoefler

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Stephan Wenzel Jahn

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

13 July 2016

1 reference

6 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

469

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

371-384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27412632%20AND%20SRC:MED&resulttype=core&format=json

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Cancer: Pinprick diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tumor heterogeneity: causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intra-tumour heterogeneity: a looking glass for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Predicting mutation outcome from early stochastic variation in genetic interaction partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Central dogma at the single-molecule level in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Insight into the heterogeneity of breast cancer through next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

The evolutionary history of lethal metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intratumour heterogeneity in urologic cancers: from molecular evidence to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Cancer: evolution within a lifetime

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Novel therapeutic targets in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Clonal progression of prostate cancers from Gleason grade 3 to grade 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tracking the clonal origin of lethal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comprehensive molecular characterization of clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Parallel evolution of tumour subclones mimics diversity between tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Frequent EGFR mutations in brain metastases of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Intratumor heterogeneity: evolution through space and time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Circulating tumor cells: liquid biopsy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Liquid biopsies: genotyping circulating tumor DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tracking tumor resistance using 'liquid biopsies'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Small RNA sequencing for profiling microRNAs in long-term preserved formalin-fixed and paraffin-embedded non-small cell lung cancer tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

RNA expression analysis from formalin fixed paraffin embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Developments in in situ hybridisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tyramide signal amplification for DNA and mRNA in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Whole-Transcriptome profiling of formalin-fixed, paraffin-embedded renal cell carcinoma by RNA-seq

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Single-cell RNA-seq: advances and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Complete solubilization of formalin-fixed, paraffin-embedded tissue may improve proteomic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

The use of formalin fixed wax embedded tissue for proteomic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

A MALDI-Mass Spectrometry Imaging method applicable to different formalin-fixed paraffin-embedded human tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

The challenge of on-tissue digestion for MALDI MSI- a comparison of different protocols to improve imaging experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

MALDI TOF imaging mass spectrometry in clinical pathology: a valuable tool for cancer diagnostics (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Multiplexed ion beam imaging of human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Somatic copy number alterations by whole-exome sequencing implicates YWHAZ and PTK2 in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

A method to evaluate genome-wide methylation in archival formalin-fixed, paraffin-embedded ovarian epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tissue microarrays for rapid linking of molecular changes to clinical endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Genetic and phenotypic diversity in breast tumor metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Circulating tumor DNA as a liquid biopsy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Genomic Classification of Cutaneous Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Multiple intratumoralKRASmutations can clonally segregate to different lymph node metastases in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Clinical application of circulating tumor cells in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-016-1987-9

Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas

21 January 2018

1 reference

12 December 2020

Tumor heterogeneity confounds and illuminates: assessing the implications

1 reference

12 December 2020

Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ,

1 reference

12 December 2020

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

1 reference

12 December 2020

Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines

1 reference

12 December 2020

In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival

1 reference

12 December 2020

Tissue Heterogeneity as a Pre-analytical Source of Variability

1 reference

12 December 2020

Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer

1 reference

12 December 2020

K-ras mutations and cetuximab in colorectal cancer

1 reference

12 December 2020

10.1007/S00428-016-1987-9

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/56skaf6s3nhpjiau4anjiczu6a

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_56skaf6s3nhpjiau4anjiczu6a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/56skaf6s3nhpjiau4anjiczu6a

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/56skaf6s3nhpjiau4anjiczu6a

1 reference

30 July 2022